LY4064809

DRUG4 trials

Sponsors

Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, Eli Lilly and Company

Conditions

Breast NeoplasmsHealthyNeoplasm Metastasis

Phase 1

A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants

CompletedNCT06991179

Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyHealthy

Start: 2025-05-20End: 2025-09-02Updated: 2025-09-23

A Study of LY4064809 in Healthy Adult Chinese Participants

CompletedNCT07247357

Eli Lilly and CompanyHealthy

Start: 2025-10-24End: 2025-12-16Updated: 2026-01-16

A Study of [14C]-LY4064809 in Healthy Participants

CompletedNCT07519525

Eli Lilly and CompanyHealthy

Start: 2026-03-27End: 2026-05-26Updated: 2026-06-08

Phase 3

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

RecruitingNCT07174336

Eli Lilly and CompanyBreast Neoplasms, Neoplasm Metastasis

Start: 2025-12-22End: 2033-05-01Target: 800Updated: 2026-09-08

Related Papers

A phase 1/2 trial of tersolisib (LY4064809/STX-478), a pan-mutant-selective PI3Kα inhibitor (PI3Kαi), in <i>PIK3CA</i> -mutant advanced solid tumors: Updated results from PIKALO-1.

Journal of Clinical Oncology2026-05-27

Abstract 5130: Identification and characterization of pan-mutant selective PI3Kα inhibitors with the capability of PI3Kα H1047R protein degradation

Cancer Research2026-04-03